INTRODUCTION
In patients with acute pulmonary embolism (PE), right ventricular (RV) dysfunction results from mechanical obstruction of the pulmonary vasculature, pulmonary arterial vasoconstriction, and inflammation of the RV muscle (1) .
Hypothesized mechanisms of RV inflammation include the accumulation of neutrophils and monocytes in the RV outflow track, and elevated circulating concentrations of myeloperoxidase and other inflammatory biomarkers associated with PE (2, 3).
Parenteral anticoagulation remains the primary acute treatment for PE (4) .
Heparins inhibit the action of thrombin, allowing the unopposed effect of endogenous plasmin to degrade clot volume over a period of days to weeks (5) .
Since the acute development of RV dysfunction in association with acute PE increases the risk of death from PE, studies have assessed the efficacy and safety of thrombolytic therapy for these patients (6) . Fibrinolytic agents allow faster clot size reduction than heparins, but they have an increased risk of haemorrhage (7) . In addition, approximately 16% of patients with PE have a contraindication to anticoagulation, and 30% have a contraindication to fibrinolysis (8) .
Attenuation of the inflammatory response in patients who have acute PE and associated with RV dysfunction may improve patient outcomes. A rat model of PE by Watts et al suggested that administration of ketorolac reduced RV inflammatory genes, reduced neutrophil influx, and improved RV function in the setting of experimental PE (9) . This study assessed the efficacy of diclofenac for improving RV dysfunction in intermediate-risk PE patients who received standard anticoagulation.
METHODS
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Study design
The AINEP trial (NCT01590342) was a single center prospective, randomized, blinded, parallel-group, placebo-controlled study that evaluated the hypothesis that therapy with diclofenac would improve RV function in patients who had intermediate-risk acute PE and associated RV dysfunction. Patients were recruited between 2013 and 2016 from a tertiary university hospital in Madrid, Spain. The study was conducted in accordance with the Declaration of Helsinki, was approved by the local ethics committee, and required written informed consent for participation.
Study patients
Consecutive adult patients who had an objective diagnosis of PE were considered for inclusion in the study if they had: 1) onset of symptoms since no more than 10 days, 2) normal blood pressure (systolic blood pressure > 100 mmHg), and 3) echocardiographic RV dysfunction detected within 12 hours after the diagnosis of PE. For the diagnosis of PE, confirmatory testing required a high probability ventilation-perfusion (V/Q) scintigraphy (10), or a positive contrastenhanced, PE-protocol, helical chest multi-detector computerized tomography (CT) for PE (11) .
Study exclusion criteria consisted of a history of chronic pulmonary hypertension, bronchial asthma, or severe heart failure. Patients were also excluded if they had had clinically relevant bleeding, major surgery or trauma within the last month, or if they had a hemorrhagic diathesis, active peptic ulcer, Crohn's disease or ulcerative colitis, or severe hepatic or renal failure. Exclusion criteria also included use of oral anticoagulation in the last two weeks, pregnancy, lactation, or less than 30 days post-partum.
Randomization and treatment
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Eligible patients were randomly allocated in a 1:1 ratio to receive diclofenac or placebo. Treatments were randomly allocated at the Pharmacy of Ramon y Cajal Hospital (Madrid, Spain) with a computer-generated list of random number in blocks of four. Copies of the randomization code were kept in sealed, sequentially numbered, opaque envelopes at the pharmacy.
Patients who were assigned to receive diclofenac were given an intravenous (IV) infusion of diclofenac (75mg, 3 mL) given over 30 minutes, two doses 12 hours apart in the first 24 hours after randomization. Patients assigned to placebo were given an IV infusion that had the same volume and appearance as for diclofenac, and they had a similar infusion duration and schedule. Diclofenac and placebo solutions were provided by the local pharmacy.
All patients received standard anticoagulation with subcutaneous low-molecularweight heparin (LMWH) enoxaparin (1 mg/Kg/12 hours). An oral vitamin K antagonist was started on the third day after randomization. LWMH was discontinued after the INR was at least 2.0 for two consecutive days.
Echocardiography assessment
The study required that patients undergo TTE within 12 hours after diagnosis of PE. Trained and certified local cardiologists, blinded to the patient's clinical data and the time of the echocardiography (i.e., before or after treatment), interpreted each echocardiogram, and these measurements were used for analyses. The study defined echocardiographic RV dysfunction as the presence of, at least, two of the following criteria: i) RV diastolic diameter > 30 mm in the parasternal window; ii) RV diameter > left ventricle diameter in the apical or subcostal space; iii) RV free wall hypokinesis; and iv) estimated pulmonary artery systolic pressure > 30 mm Hg (12) .
A core laboratory that was blinded to group assignment measured baseline RV/LV ratios, and these measures were compared with the data obtained by local cardiologists to assess interobserver agreement.
Follow-up and outcome assessment
Study personnel assessed study participants for death, hemodynamic decompensation (or collapse), bleeding, stroke, recurrent PE, and serious adverse events for 30 days post-randomization. An independent clinical-events committee, whose members were unaware of the treatment-group assignments, adjudicated all efficacy and safety outcomes.
The primary efficacy outcome of the study was the resolution of echocardiographic RV dysfunction at 48 hours after randomization. The secondary efficacy outcome was the resolution of RV dysfunction at 7 days after randomization. The primary safety outcome was major bleeding within 7 days after randomization. Major bleeding was defined as overt bleeding associated Between-group continuous data were compared with the 2-sided unpaired t test or Wilcoxon rank sum test. Between-group ordinal data were compared with the exact Mantel-Haenszel chi-square test. Interobserver agreement for the echocardiographic baseline RV/LV ratio between the investigator and core laboratory measurements was assessed by Bland-Altman analysis (15) .
RESULTS
Patients
From January 2013 through December 2016, a total of 34 patients were enrolled.
Of these patients, 17 were randomly assigned to treatment with diclofenac, and 17 were randomly assigned to placebo (Figure 1) . The two treatment groups had similar baseline demographic, clinical, and medical history data ( Table 1) . The median age in the study population was 75 years and 65% were women. All patients were normotensive at randomization.
Echocardiography
With all patients having RV dysfunction at randomization, it persisted in 59% (95% confidence interval [CI], 33-82%) of the diclofenac group and in 76% (95% CI, 50-93%) of the placebo group at 48 hours ( Table 2) , which did not meet statistical significance for the primary efficacy outcome (59% vs. 76%,
A C C E P T E D M A N U S C R I P T
Diclofenac for intermediate-risk PE Thromb Res respectively; P = 0.46). By day 7, the diclofenac and placebo groups had similar proportions (35%) of patients who had persistent RV dysfunction ( Table 2 
Safety outcomes
Only one major bleeding event occurred ( Table 3 ). An 81 year-old patient in the placebo group developed cardiovascular collapse 3 days after initially being treated with anticoagulant therapy. He received "rescue" thrombolytic therapy.
Two days later, a major gastrointestinal bleeding event led to discontinuation of anticoagulation and placement of an inferior vena cava (IVC) filter. Sixteen days after the diagnosis of acute PE, he developed a new symptomatic deep vein thrombosis. At 30 days, none of the 34 randomized patients had died.
Interobserver agreement
In 32 (94%; 95% CI, 80-99%) of 34 analyzed patients, there was agreement between investigators and core laboratory for identifying patients with a baseline RV/LV ratio > 1. The mean (± SD) difference in the baseline echocardiographic RV/LV ratio between investigator and core laboratory measurements was 0.03 ± 0.10 ( Figure 3) .
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DISCUSSION
We conducted the first registered (clinicaltrials.gov) randomized trial of diclofenac versus placebo in normotensive patients who had acute symptomatic PE associated with RV dysfunction. Between the two randomized treatment groups, this study did not detect a statistically significantly greater improvement in the proportion of patients who had RV dysfunction at 48 hours or at 7 days after randomization. Many patients in both randomized groups had improvements in multiple echocardiographic variables related to RV dysfunction at 48 hours, and most patients showed such improvement at 7 days after randomization, and statistically significant within group improvements occurred for most variables at both time points. Since poor enrollment led to early termination of the study, a type II error could have occurred, since the study only had a power of 18% to detect a difference in the primary outcome. By extrapolation, these data imply that a follow-up study in a similar patient population would require 118 randomized patients in each treatment group to be able to detect a betweengroup difference of 17% in the proportion of patients who normalized their echocardiographic findings. Thus, this work provides necessary preliminary data for a larger and more definitive clinical trial. (16), and studies have demonstrated their association with increased mortality in chronic heart failure (17) and myocardial infarction (18) .
We chose to use a dose of diclofenac that studies of analgesia successfully used (20, 21) .
Regarding the safety of NSAID use among patients with venous thromboembolism receiving anticoagulant therapy, studies have shown an association between NSAID use and an increased risk of clinically relevant and major bleeding (22) . Although we did not design this trial of diclofenac vs placebo to meet non-inferiority criteria for bleeding complications, we so far feel reassured that none of the patients randomized to the 2 doses of diclofenac had a major bleeding complication. Of note, the eligibility criteria for the study did exclude some of the patients at higher risk for bleeding.
Different groups of investigators have not agreed upon standard definitions for echocardiographic findings of RV dysfunction (23) . However, previous studies supported the use of this study's primary outcome (24) . Similar to a previous trial that assessed the efficacy and safety of catheter-directed thrombolysis in patients who enrolled with intermediate-risk PE, our data suggested an excellent core lab / local clinician agreement of 94% for identifying patients a baseline RV/LV ratio > 1. Also supporting the use of RV dysfunction for assessing efficacy, our study showed that resolution of RV dysfunction was achieved in 65% of patients at 7 days in both randomized groups, similar to many randomized clinical trials of rt-PA versus heparin that demonstrated a catch-up phenomenon in the heparin group, with initially worse hemodynamic parameters that later became similar to the thrombolytic group at 1 week of follow-up and beyond (25) . Futures studies could assess for NSAID effects on other 
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Medical history
Chronic pulmonary disease, n (%) 0 ( Between group comparison P = 0.53 P = 0.30 P = 0.39 P = 0.14 P = 0.55
TAPSE, mm
Within group comparison N/A N/A N/A P < 0.001 P < 0.001 P < 0.001 P < 0.001
Abbreviations: RV, right ventricle; N/A, not applicable; LV, left ventricle; TAPSE, tricuspid annular pulmonary systolic excursion; SD, standard deviation.
* Measured in the parasternal window. ¶ In the apical or subcostal space. 
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HIGHLIGHTS
 Anti-inflammatory drugs may facilitate the reversal of RV dysfunction in PE.
 We assessed the efficacy of diclofenac for reversing RV dysfunction in PE.
 Our study is inconclusive as to a potential benefit of diclofenac in PE.
